[{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"Axcelead","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Superluminal Medicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Superluminal Medicines \/ Superluminal Medicines","highestDevelopmentStatusID":"3","companyTruncated":"Superluminal Medicines \/ Superluminal Medicines"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Superluminal Medicines","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Superluminal Medicines \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Superluminal Medicines \/ RA Capital Management"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Superluminal Medicines","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Superluminal Medicines \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Superluminal Medicines \/ RA Capital Management"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Superluminal Medicines","amount2":1.3,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.3,"dosageForm":"Undisclosed","sponsorNew":"Superluminal Medicines \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Superluminal Medicines \/ Eli Lilly"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Superluminal Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Superluminal Medicines \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Superluminal Medicines \/ Undisclosed"}]